Navigation Links
Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
Date:7/17/2008

- Approval of Second IND Marks Major Corporate Milestone and Advances

Clinical Program -

ANN ARBOR, Mich., July 17 /PRNewswire/ -- Meditrina Pharmaceuticals, Inc. today announced the approval of its second investigational new drug (IND) application for a Phase IIb dose ranging clinical trial to study MPI-676, the Company's aromatase inhibitor (AI), in combination with estrogen and progestin for the treatment of endometriosis. MPI-676 is the newest addition to Meditrina's clinical stage product portfolio that currently includes Femathina(TM) (MPI-674), an AI that Meditrina is repurposing for the treatment of endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding. Meditrina recently completed a global licensing agreement to make, develop and commercialize products, including MPI-676, under AstraZeneca's IP and know-how regarding the use of AIs in combination with estrogen and progestin to treat endometriosis.

"This IND for MPI-676 marks another major milestone in our robust clinical program focused on addressing women's reproductive system disorders," said James Symons, Ph.D., Vice President, Clinical Development, Meditrina Pharmaceuticals, Inc. "Based on the encouraging proof of concept and strong safety data established for MPI-676, we look forward to selecting the dose for Phase III pivotal trials, which will be at a dose lower than for which AstraZeneca has already established two-year chronic use safety data in their breast cancer prevention trials and is cited in the anastrozole product label. These data will advance development of MPI-676 and help us bring this important new treatment to women suffering from endometriosis, a painful and debilitating condition."

This US-based, multi-center, placebo-controlled, double-blinded study will identify the maximally efficacious dose of MPI-676 to investigate in the pivotal Phase III program. The Phase IIb dose ra
'/>"/>

SOURCE Meditrina Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
3. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
4. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
5. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
6. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
7. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
8. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
9. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2008)...NAA says: Wrong Question Asked. Wrong Children Stu.... 3 /PRNewswire-USNewswire/ -- A Centers for Disea...ay claims there is no link,between the MMR vaccine...,says this study does nothing to dispel the growin...and raises several questions concerning design,and...
(Date:9/3/2008)... - Long term follow up results from chronically in...xceed positive data obtained earlier in 2008, - ...cant and long-term antiviral effect of ther... way and strongly support move into a second gener...nt IC31(R) acting through TLR ...
(Date:9/3/2008)... GAITHERSBURG, Md., Sept. 3 /- Panace...ce of U.S. Patent Number 7,413,737 covering,antibo...roxylase (HAAH), a,proprietary human cancer biomar...developed in collaboration with the Massachusetts ...usive, worldwide rights to this patent,for develop...
(Date:9/3/2008)... Company Focuses Operations, Updates Zingo Launch ...ation Strategy Conference Call To...Sept. 3 /- Anesiva,Inc. (N...ll restructure,operations to focus on commercial a...s transition to a specialty pharmaceutical pain ma...
Breaking Medicine Technology:CDC Misses Target With Flawed MMR/Autism Study 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5ZONARE Names Marcotte Chief Financial Officer 4588 1ZONARE Names Marcotte Chief Financial Officer 4588 2New Survey Shows Majority of Employers Rank Smoking as One of Their Greatest Priority Health Issues But Only 2 Percent Provide Comprehensive Smoking 4584 1New Survey Shows Majority of Employers Rank Smoking as One of Their Greatest Priority Health Issues But Only 2 Percent Provide Comprehensive Smoking 4584 2New Survey Shows Majority of Employers Rank Smoking as One of Their Greatest Priority Health Issues But Only 2 Percent Provide Comprehensive Smoking 4584 3New Survey Shows Majority of Employers Rank Smoking as One of Their Greatest Priority Health Issues But Only 2 Percent Provide Comprehensive Smoking 4584 4New Survey Shows Majority of Employers Rank Smoking as One of Their Greatest Priority Health Issues But Only 2 Percent Provide Comprehensive Smoking 4584 5Leading Edge Research Underway in Fall Prevention for Seniors 1502 1Leading Edge Research Underway in Fall Prevention for Seniors 1502 2Leading Edge Research Underway in Fall Prevention for Seniors 1502 3Genzyme and Sunway to Collaborate on Gene Therapy Program in China 1498 1Genzyme and Sunway to Collaborate on Gene Therapy Program in China 1498 2Genzyme and Sunway to Collaborate on Gene Therapy Program in China 1498 3Genzyme and Sunway to Collaborate on Gene Therapy Program in China 1498 4
...age of More Than Two Hours Per Day, RESEARCH TRIAN...ing the once daily, investigational medication REQ...lease Tablets to,Parkinson,s patients, existing le..., time, allowing patients to continue,their daily ...,describes the return of Parkinson,s symptoms as a...
...ppresses Amyloid Plaque Formation, ANNAPOLIS, Md.,... a leading biodefense company specializing in the ...ermeasures against chemical,and biological terrori...nant butyrylcholinesterase (rBChE) research progra... Conference on,Alzheimer,s and Parkinson,s Disease...
Other Medicine Technology:Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 2Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 3Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 4Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 5PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 2PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 3PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 4PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 5PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 6
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...on is putting his best foot forward with respect t...ions are rife for the parties’ annual spring// con...terated that curtailing health problems like obesi...and the risk of sexually transmitted diseases is v...
...ch age of modern medicine, could it be possible to...ugh the power //of meditation? According to a stud...technique can significantly reduce the severity of...lts of this study indicate that transcendental med...
... insulin therapy on the medical-surgical wards res...dividualized management// in patients with diabeti...may be possible. “This is the first randomized ... subcutaneous insulin protocol on medical-surgical...
...c, which is present in every part of the body, cou...study that could help// in the development of new ...ribute to the formation of plaques in the brains o... disease. It is also vital for the healthy working...
Other Medicine News:Health News:Transcendental Meditation Can Help 2Health News:New Research May Pave the Way for Shorter Hospital Stays for Diabetes Patients 2
The HYRYS™ 2 densitometer is reflective of Sebia's expertise in the development and design of imaging systems and densitometers utilized in the electrophoresis field.
Hydragel K20 is Sebia's quality line of manual agarose gel electrophoresis products. Samples are applied utilizing the same patented applicator combs that is used for sample application on the HYDRAS
Eliminating the need for any manual pipetting, the HydraPLUS delivers precise micro-volumes of sample directly from primary tubes to four HYDRASYS sample applicators contained in a built-in humidity
Handheld Digital Retinal Camera
Medicine Products: